PT - JOURNAL ARTICLE AU - Gaibazzi, Nicola AU - Tuttolomondo, Domenico AU - Guidorossi, Angela AU - Botti, Andrea AU - Tedeschi, Andrea AU - Martini, Chiara AU - Mattioli, Maria TI - Smoking Prevalence is Low in Symptomatic Patients Admitted for COVID-19 AID - 10.1101/2020.05.05.20092015 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.05.20092015 4099 - http://medrxiv.org/content/early/2020/05/10/2020.05.05.20092015.short 4100 - http://medrxiv.org/content/early/2020/05/10/2020.05.05.20092015.full AB - There is currently little information regarding the role of active smoking in predisposing to SARS-CoV-2 infection. This retrospective case series includes 441 patients with confirmed Covid-19, who were consecutively admitted between March 5 and March 31, 2020, at a tertiary referral center in Parma, Northern Italy, with laboratory-confirmed COVID-19. 273 (62%) patients were males. Median age was 71 y/o, 156 patients (35%) died during hospitalization and 285 (65%) were discharged because clinically healed. 21 patients (5%) were active smokers and 44 (10%) were ex-smokers, while 376 (85%) were non-smokers. Male sex, history of prior cardiovascular disease, D-dimer and C-reactive protein were significantly more prevalent or higher in the subgroup of 156 patients who died during hospital stay, compared with 285 patients discharged alive. Active smokers were only 21, this number corresponding to less than 5% prevalence of active smokers, which is disproportionately low compared with the 24% prevalence of smokers in the general Italian population (p<0.001). The very low prevalence of smokers in our COVID-19 cohort seemingly replicates the findings that can be extracted from descriptive tables in Chinese reports and also in the recent US reports from New York City. The current study is useful since it suggests that smokers may carry some type of protective mechanism from symptomatic SARS-CoV-2 infection, although this should definitely be confirmed in specifically-designed, controlled studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe identified data can be made available upon reasonable request by other investigators.